Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) expanded its collaboration with Oxford Nanopore Technologies and broadened commercial rights to develop a portfolio of genetics products on Oxford Nanopore platforms.
The agreement formally extends the partnership through 2032, builds on the March 2025 launch of the AmplideX Nanopore Carrier Plus Kit, and establishes a framework to define and propose future targeted enrichment sequencing kits for screening and diagnosis of heritable genetic disorders.
The companies said the enhancement will streamline coordination on development and commercialization and support Bio-Techne's diagnostics growth strategy by accelerating innovation and portfolio planning.
Positive
- Collaboration extended through 2032
- Expanded commercial rights to develop a genetics product portfolio
- Framework established to propose future targeted enrichment sequencing kits
Negative
- None.
Insights
Expanded collaboration with Oxford Nanopore extends commercialization rights and partnership through
Bio‑Techne gains broader commercial rights to develop targeted enrichment sequencing kits on Oxford Nanopore platforms, building on the AmplideX® Nanopore Carrier Plus Kit launched in
Key dependencies include successful development, regulatory clearance where required, and effective commercialization execution with Oxford Nanopore. The extension to
Watch for new kit announcements, regulatory filings, and adoption metrics over the next 12–36 months; those milestones will show whether the agreement translates into measurable diagnostics revenue and broader market penetration.
- Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit
- Establishes a framework to define and propose future portfolios
- Extends collaboration through 2032, reinforcing Bio-Techne's diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies
Building upon the successful launch of the AmplideX® Nanopore Carrier Plus Kit in March 2025, the enhanced collaboration streamlines coordination on the development and commercialization of a broader portfolio of targeted enrichment sequencing kits for the screening and diagnosis of heritable genetic disorders.
"This expanded agreement underscores our commitment to advancing genetic testing solutions that simplify workflows and deliver richer insights for laboratories worldwide," said Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By deepening our collaboration with Oxford Nanopore, we are accelerating innovation in diagnostics and creating a foundation for future portfolios."
"We're pleased to expand our collaboration with Bio-Techne to bring new genetic testing solutions to laboratories worldwide. By combining Bio-Techne's diagnostics expertise and innovations with our advanced molecular sensing platform, together we can make testing faster, simpler, and more accessible," said Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, and YouTube.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies' vision is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Company has developed a new generation of nanopore-based sensing technology that is currently used for information-rich, rapid, accessible and affordable DNA and RNA analysis. The platform is also being developed for the analysis of proteins and metabolites. The technology is being used in more than 125 countries to understand the biology of humans, plants, animals, bacteria, viruses and environments, as well as a range of diseases including cancer.
Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: https://nanoporetech.com/
Contact:
Corporate Communications
media.relations@bio-techne.com
Investor Relations
David.clair@bio-techne.com
Oxford Nanopore
Media@nanoporetech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-oxford-nanopore-technologies-expand-agreement-to-accelerate-development-of-genetics-portfolio-through-2032-302579234.html
SOURCE Bio-Techne Corporation
FAQ
What did Bio-Techne announce about its deal with Oxford Nanopore on October 9, 2025 (TECH)?
How does the expanded agreement affect Bio-Techne's diagnostics strategy (TECH)?
Which product launch does the expanded agreement build upon for Bio-Techne (TECH)?
What product types will Bio-Techne and Oxford Nanopore coordinate under the extended deal (TECH)?
Will the agreement create a process for future product proposals between the companies (TECH)?
